Evidence map›Paper›PMID 31438631›Full record

ArticleBiomolecules2019

A Multi-Biochemical and In Silico Study on Anti-Enzymatic Actions of Pyroglutamic Acid against PDE-5, ACE, and Urease Using Various Analytical Techniques: Unexplored Pharmacological Properties and Cytotoxicity Evaluation.

Miroslava Šudomová, Sherif T S Hassan, Haroon Khan, Mahsa Rasekhian, Seyed Mohammad Nabavi

Open access · goldAbstract read
In one paragraph

Article in Biomolecules, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.6field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 36 citations in OpenAlex.

  1. Article
  2. Article
  3. Computational andBiomedical reports · 2024
    Article
  4. AnHeliyon · 2024
    Article
  5. Article
  6. InhibitingPharmaceuticals (Basel, Switzerland) · 2023
    Article
  7. Article
  8. Homology Modeling,Frontiers in cellular and infection microbiology · 2022
    Article
  9. Observational
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 3 countries.

Miroslava ŠudomováMuseum of literature in Moravia, Klášter 1, 664 61 Rajhrad, Czech Republic.
Sherif T S HassanDepartment of Natural Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackého tř. 1946/1, 612 42 Brno, Czech Republic. sherif.hassan@seznam.cz.ORCID 0000-0003-3922-2738
Haroon KhanDepartment of Pharmacy, Abdul Wali Khan University, Mardan 23200, Pakistan.ORCID 0000-0002-1736-4404
Mahsa RasekhianPharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah 6734667149, Iran.
Seyed Mohammad NabaviApplied Biotechnology Research Center, Baqiyatallah University of Medical Sciences, Tehran 14359-16471, Iran. nabavi208@gmail.com.
Abdul Wali Khan University Mardan · PKBaqiyatallah University of Medical Sciences · IRKermanshah University of Medical Sciences · IRUniversity of Veterinary Sciences Brno · CZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the current study, pyroglutamic acid (pGlu), a natural amino acid derivative, has efficiently inhibited the catalytic activities of three important enzymes, namely: Human recombinant phosphodiesterase-5A1 (PDE5A1), human angiotensin-converting enzyme (ACE), and urease. These enzymes were reported to be associated with several important clinical conditions in humans. Radioactivity-based assay, spectrophotometric-based assay, and an Electrospray Ionization-Mass Spectrometry-based method were employed to ascertain the inhibitory actions of pGlu against PDE5A1, ACE, and urease, respectively. The results unveiled that pGlu potently suppressed the activity of PDE5A1 (half-maximal inhibitory concentration; IC

Indexed as

Binding SitesCaptoprilCell LineCell SurvivalCyclic Nucleotide Phosphodiesterases, Type 5HumansHydroxamic AcidsInhibitory Concentration 50Molecular Docking SimulationPeptidyl-Dipeptidase AProtein Structure, TertiaryPyrrolidonecarboxylic AcidRecombinant ProteinsSildenafil CitrateSpectrometry, Mass, Electrospray IonizationSpectrophotometryACE protein, humanacetohydroxamic acidCaptoprilCyclic Nucleotide Phosphodiesterases, Type 5Hydroxamic AcidsPDE5A protein, humanPeptidyl-Dipeptidase APyrrolidonecarboxylic AcidRecombinant ProteinsSildenafil CitrateUreaseangiotensin-converting enzymeanti-enzymatic propertiescytotoxicityESI-mass spectrometryphosphodiesterase 5pyroglutamic acidurease

Identifiers

PMID31438631
PMCPMC6770154
OpenAlexW2969273806

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.